ERNA (Ernexa Therapeutics) Accounts Receivable : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ernexa Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Ernexa Therapeutics's accounts receivables for the quarter that ended in Dec. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Ernexa Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Ernexa Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $-0.04.

Ernexa Therapeutics Accounts Receivable Historical Data

The historical data trend for Ernexa Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ernexa Therapeutics Accounts Receivable Chart

Ernexa Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Receivable

Ernexa Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Ernexa Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Ernexa Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Ernexa Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.001	*	91
=	0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Ernexa Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Ernexa Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1.729	+	0.75 * 0	+	0.5 * 0	-	3.568
-	0.001	-	0)	/	51.386
=	-0.04

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Ernexa Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Ernexa Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Ernexa Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ernexa Therapeutics Inc (NAS:ERNA) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141

Website

https://www.ernexatx.com

Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.

Executives

Charles Cherington	10 percent owner	ONE BOW STREET, CAMBRIDGE MA 02138
Dorothy J Clarke	director	C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141
Brant Binder	director	C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066
Richard W Wagner	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451
Curtis W Huft	10 percent owner	4510 LAMESA HWY, SNYDER TX 79549
Freebird Partners Lp	10 percent owner	2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
Freebird Investments Llc	10 percent owner	2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
John D Halpern	10 percent owner
Nicholas Jason Singer	director	1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131
William A. Wexler	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Gregory Fiore	director	10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121
Andrew C. Jackson	officer: Chief Financial Officer	11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Matthew Angel	officer: Interim President and CEO	10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127
Heather B Redman	director	TWO NORTH NINTH STREET, ALLENTOWN PA 18101
Erin S. Enright	director	666 PLAINSBORO ROAD, PLAINSBORO NJ 08536